OXFORD, UK – 10 April 2019 – Enesi Pharma, an innovative pharmaceutical company developing unique injectable solid dose drug-device vaccine products, will participate at the World Vaccine Congress, taking place on 14-17 April in Washington, DC. The Company will showcase its ImplaVax® solid dose, needle-free device and formulation technology for the development of novel vaccine products at Booth #206.
In addition, David Hipkiss, Enesi’sCEO, will chair the following sessions on Tuesday 16 April
• 2:40pm Eastern time (ET) – Vaccine Production for Outbreaks
• 4:10pm ET – Alternative Delivery Platforms
For the past 18 years, the World Vaccine Congress Washington has evolved and grown into the leading vaccines congress globally, with over 300 speakers and 1,500 attendees. The event is a leading forum for discussing how cutting-edge research efforts can be integrated with pharma, biotech, academia and government to produce more and better vaccines to the market. In addition, the congress is expanding into newer topic areas such as BioDefense, Big Data and Bioinformatics in a greater capacity, engaging more profiles from Army, Department of Defense, non-profits and national representatives in healthcare.